106
Participants
Start Date
April 2, 2018
Primary Completion Date
January 3, 2025
Study Completion Date
January 3, 2025
Sildenafil
Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.
Placebo
Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
Cohen Children's Medical Center of NY, New Hyde Park
Golisano Children's Hospital - University of Rochester Medical Center, Rochester
WakeMed Health and Hospitals, Raleigh
University of Florida College of Medicine Jacksonville-Wolfson Children's Hospital, Jacksonville
University of Florida Jacksonville Shands Medical Center, Jacksonville
University of Mississippi Medical Center, Jackson
University of Kentucky, Lexington
University of Illinois at Chicago, Chicago
Wesley Medical Center, Wichita
Ochsner Baptist Medical Center, New Orleans
University of Arkansas for Medical Sciences, Little Rock
University of Oklahoma, Oklahoma City
Children's Hospital of Nevada at UMC, Las Vegas
Monmouth Medical Center, Long Branch
Health Sciences Centre Hospital, Winnipeg
Collaborators (1)
Duke University
OTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
The Emmes Company, LLC
INDUSTRY
University of North Carolina, Chapel Hill
OTHER